Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

Figure 3

Effect of anti-TNF treatment on peripheral blood B cells in rheumatoid arthritis patients. (a) No effect of anti-TNF treatment on peripheral blood (PB) CD19+ cells, CD19+HLA-DR+ cells, and CD19+CD27+ cells in rheumatoid arthritis (RA) patients (n = 7). B-cell depletion is specific to rituximab therapy. (b) Treatment with rituximab does not affect the proportion of total CD4+ T cells, activated CD4+HLA-DR+ T cells and CD4+CD25+ T cells in the PB of RA patients.

Back to article page